Efficacy News and Research

RSS
pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida reports revenues of $699,000 for fourth quarter 2012

Concentrated high-protein liquid fortifier boosts ICU babies’ growth

Concentrated high-protein liquid fortifier boosts ICU babies’ growth

BG-12 effective for relapsing–remitting multiple sclerosis

BG-12 effective for relapsing–remitting multiple sclerosis

ESMO Designated Center of Integrated Oncology and Palliative Care accreditation for 16 new centers

ESMO Designated Center of Integrated Oncology and Palliative Care accreditation for 16 new centers

Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection

Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

Sleep medicine and research: an interview with James K. Walsh

Sleep medicine and research: an interview with James K. Walsh

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Greenhouse-grown corn seeds could help treat lysosomal storage disease

Greenhouse-grown corn seeds could help treat lysosomal storage disease

NCI awards Provocative Questions grant to Mount Sinai School of Medicine researchers

NCI awards Provocative Questions grant to Mount Sinai School of Medicine researchers

Case Western Reserve researcher to identify mechanistic link between psoriasis and CVD

Case Western Reserve researcher to identify mechanistic link between psoriasis and CVD

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Antiwasting supplements provide moderate improvements in child health

Antiwasting supplements provide moderate improvements in child health

Boehringer Ingelheim files MAA with EMA for afatinib approval

Boehringer Ingelheim files MAA with EMA for afatinib approval

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.